# Bromantane
*Source: https://psychonautwiki.org/wiki/Bromantane*

## Dosage & Duration

### Oral

**Dosage:**
- Bioavailability: 42%[1]
- Threshold: < 10 mg
- Light: 10 - 50 mg
- Common: 50 - 100 mg
- Strong: 100 - 200 mg
- Heavy: 200 mg +

**Duration:**
- Total: 6 - 10 hours
- Onset: 30 - 60 minutes
- Peak: 2 - 4 hours

**Bromantane** (trade name **Ladasten / Ладастен** ) is a Russian pharmaceutical substance developed in the late 1980s that possesses both [stimulant](https://psychonautwiki.org/wiki/Stimulant) and [anxiolytic](https://psychonautwiki.org/wiki/Anxiety_suppression) properties. Although it is a commonly used medication in Russia and surrounding countries, it has not gained widespread recognition or pharmaceutical use in other countries. During the 1996 Olympic Games in Atlanta, 5 different Russian athletes tested positive for bromantane use.

A study conducted on human subjects displayed bromantane's ability to improve endurance and work capacity during stressful and intense conditions. This is because bromantane works as an actoprotector, a substance that makes the body more stable under physical duress without increasing oxygen consumption.

## Chemistry

Bromantane is a chemical derivative of [adamantane](https://psychonautwiki.org/wiki/Adamantane) , a polyhedral organic compound containing four fused cyclohexane rings. Bromantane's structure consists of adamantane bound at R 2 to a nitrogenous group which is in turn bonded to a phenyl ring substituted at R 4 with a bromine group.

## Pharmacology

Bromantane is atypical among [stimulants](https://psychonautwiki.org/wiki/Stimulant) in the sense that it inhibits [serotonin](https://psychonautwiki.org/wiki/Serotonin) reuptake in addition to inhibiting [dopamine](https://psychonautwiki.org/wiki/Dopamine) reuptake. It also increases levels of [norepinephrine](https://psychonautwiki.org/wiki/Noradrenaline) , but its means of doing so are unclear. Bromantane's [anxiolytic](https://psychonautwiki.org/wiki/Anxiety_suppression) properties are due to its strengthening of GABA-ergic mediation.

Unlike typical stimulants such as [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , bromantane's effects come primarily through the upregulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase (L-DOPA decarboxylase). Rodent studies have shown a 2-2.5x increase in these enzymes following administration of bromantane, and their upregulation causes a downstream increase in levels of dopamine, serotonin and epinephrine.

Although not relevant at clinical dosages, bromantane has been found to produce [anticholinergic](https://psychonautwiki.org/wiki/Deliriant) effects, including both antimuscarinic and antinicotinic actions, at very high doses in animals.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- - **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** - It is generally not described as forced and is mild comparing to that produced by typical stimulants like amphetamine.
- **[Stamina enhancement](https://psychonautwiki.org/wiki/Stamina_enhancement)**
- **[Dehydration](https://psychonautwiki.org/wiki/Dehydration)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Vasoconstriction](https://psychonautwiki.org/wiki/Vasoconstriction)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Muscle relaxation](https://psychonautwiki.org/wiki/Muscle_relaxation)** [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Tactile enhancement](https://psychonautwiki.org/wiki/Tactile_enhancement)** - Bromantane can cause warm pleasurable skin feeling simillar to that produced by empathogens like MDMA but the effect is far less pronounced. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **[Teeth grinding](https://psychonautwiki.org/wiki/Teeth_grinding)** - Although bromantane has muscle relaxing properties it can cause jaw clenching especially when mixed with caffeine. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*] ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)** - Bromantane produces anxiety supression which is unusual comparing to typical stimulants like amphetamine which can actually cause feelings of anxiety.
- **[Focus enhancement](https://psychonautwiki.org/wiki/Focus_enhancement)**
- **[Thought acceleration](https://psychonautwiki.org/wiki/Thought_acceleration)**
- **[Analysis enhancement](https://psychonautwiki.org/wiki/Analysis_enhancement)**
- **[Memory enhancement](https://psychonautwiki.org/wiki/Memory_enhancement)**
- **[Motivation enhancement](https://psychonautwiki.org/wiki/Motivation_enhancement)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Wakefulness](https://psychonautwiki.org/wiki/Wakefulness)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)** - It appears less consistently and the effect is less pronounced comparing to typical stimulants like amphetamine.
## Toxicity and harm potential

### Lethal dosage

The LD 50 of bromantane in mice has been established at 8100 mg/kg.

It is strongly recommended that one use [harm reduction practices](https://psychonautwiki.org/wiki/Responsible_drug_use) when using this substance.

### Tolerance and addiction potential

Unlike other [stimulants](https://psychonautwiki.org/wiki/Stimulant) , bromantane does not seem to produce tolerance, addiction, or withdrawal symptoms upon discontinuation. Due to its irregular mechanism of action, it does not exhibit cross-tolerance with other typical stimulants, and anecdotal reports have claimed it can be used to reduce stimulant tolerance, which is caused in part by downregulation of tyrosine hydroxylase which bromantane can increase.

#### Long term effects

Bromantane has been shown to uniquely cause long-term changes to gene expression involved in dopamine metabolism in rats. It is unclear if this effect is relevant to humans.

There are multiple anecdotal reports of long-term increases in energy levels, likely from elevated dopamine, from use of bromantane for periods of several months. These effects are claimed to persist even after stopping use of the drug, although have been noted to diminish over time, on a scale of weeks to a month. In a study investigating bromantane in the treatment of neurasthenia, a persistent reduction in fatigue was noted for a month following withdrawal of the drug.

### Dangerous Interractions

Due to its mechanism of action, bromantane can cause an unexpectedly strong reaction when mixed with other stimulants such as [amphetamine](https://psychonautwiki.org/wiki/Amphetamine) , [cocaine](https://psychonautwiki.org/wiki/Cocaine) and/or [methylphenidate](https://psychonautwiki.org/wiki/Methylphenidate) . It is advised to avoid the use of stimulants with bromantane due to the potential for much stronger reactions than one would expect.

## Legal status

- **Germany** : Bromantane is not a controlled substance under the BtMG ( *Narcotics Act* ) or the NpSG ( *New Psychoactive Substances Act* ). According to §2 AMG ( *Medicines Act* ) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Bromantane can be considered legal.
- **Russia** : In Russia Bromantane has been discontinued in 2017 and will not be available in the nearest future. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]
- **Switzerland** : Bromantane is not controlled under Buchstabe A, B, C and D. It could be considered legal.
- **United States** : Bromantane is uncontrolled in the United States and has not been approved by the FDA for human use. However, this has led [nootropic](https://psychonautwiki.org/wiki/Nootropic) vendor websites to sell bromantane under the label of "not for human consumption." [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use)
- [Tianeptine](https://psychonautwiki.org/wiki/Tianeptine)
- [Memantine](https://psychonautwiki.org/wiki/Memantine)
- [Noopept](https://psychonautwiki.org/wiki/Noopept)
- [Nootropics](https://psychonautwiki.org/wiki/Nootropics)

## External links

- [Bromantane (Wikipedia)](https://en.wikipedia.org/wiki/Bromantane)
- [Bromantane (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=744)

## Literature

- Reichlin, S. (1969). Handbook of Experimental Pharmacology. The American Journal of The Medical Sciences (Vol. 258). [https://doi.org/10.1097/00000441-196911000-00008](https://doi.org/10.1097/00000441-196911000-00008)
- Krapivin, S. V, Sergeeva, S. A., & Morozov, I. S. (1993). [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]. Biulleten’ Eksperimental’noi Biologii I Meditsiny, 116(11), 515–8. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/8312546](http://www.ncbi.nlm.nih.gov/pubmed/8312546)
- Burnat, P., Payen, A., Brumant-Payen, C. Le, Hugon, M., & Ceppa, F. (1997). Bromontan, a new doping agent. The Lancet, 350(9082), 963–964. [https://doi.org/10.1016/S0140-6736(05)63310-7](https://doi.org/10.1016/S0140-6736(05)63310-7)
- Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., & Zhirnov, E. N. (2000). [The neuro- and psychophysiological effects of bromantane]. Voenno-Meditsinskii Zhurnal, 321(8), 61–5, 96. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/10998997](http://www.ncbi.nlm.nih.gov/pubmed/10998997)
- Iezhitsa, I. N., Spasov, A. A., & Bugaeva, L. I. (2001). Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicology and Teratology, 23(2), 213–222. [https://doi.org/10.1016/S0892-0362(01)00119-2](https://doi.org/10.1016/S0892-0362(01)00119-2)
- Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., & Morozov, I. S. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine, 133(4), 380–383. [https://doi.org/10.1023/A:1016206306875](https://doi.org/10.1023/A:1016206306875)
- Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomolecules and Therapeutics, 20(5), 446–456. [https://doi.org/10.4062/biomolther.2012.20.5.446](https://doi.org/10.4062/biomolther.2012.20.5.446)
- Morozov, I. S., Klimova, N. V, Karpova, T. D., & Shestopalov, S. S. (n.d.). [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. Eksperimental’naia I Klinicheskaia Farmakologiia, 62(2), 3–6. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/10340117](http://www.ncbi.nlm.nih.gov/pubmed/10340117)
- Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V, & Gaĭnetdinov, R. R. (n.d.). [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksperimental’naia I Klinicheskaia Farmakologiia, 58(4), 8–11. Retrieved from [http://www.ncbi.nlm.nih.gov/pubmed/7580761](http://www.ncbi.nlm.nih.gov/pubmed/7580761)

## References
1. ↑ Oliynyk, S., Oh, S. (September 2012).["The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762282/).*Biomolecules & Therapeutics*.**20**(5): 446–456.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.4062/biomolther.2012.20.5.446](//doi.org/10.4062%2Fbiomolther.2012.20.5.446).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1976-9148](//www.worldcat.org/issn/1976-9148).
2. ↑ Krapivin, S. V., Sergeeva, S. A., Morozov, I. S. (November 1993). "[A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]".*Biulleten’ Eksperimental’noi Biologii I Meditsiny*.**116**(11): 515–518.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0365-9615](//www.worldcat.org/issn/0365-9615).
3. ↑ Burnat, P., Payen, A., Brumant-Payen, C. L., Hugon, M., Ceppa, F. (September 1997).["Bromontan, a new doping agent"](https://linkinghub.elsevier.com/retrieve/pii/S0140673605633107).*The Lancet*.**350**(9082): 963–964.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1016/S0140-6736(05)63310-7](//doi.org/10.1016%2FS0140-6736%2805%2963310-7).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0140-6736](//www.worldcat.org/issn/0140-6736).
4. ↑ Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., Zhirnov, E. N. (August 2000). "[The neuro- and psychophysiological effects of bromantane]".*Voenno-Meditsinskii Zhurnal*.**321**(8): 61–65, 96.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0026-9050](//www.worldcat.org/issn/0026-9050).
5. ↑ 5.0 5.1 Oliynyk, S., Oh, S.-K. (30 September 2012).["The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance"](http://koreascience.or.kr/journal/view.jsp?kj=OOOMB4&py=2012&vnc=v20n5&sp=446).*Biomolecules and Therapeutics*.**20**(5): 446–456.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.4062/biomolther.2012.20.5.446](//doi.org/10.4062%2Fbiomolther.2012.20.5.446).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1976-9148](//www.worldcat.org/issn/1976-9148).
6. ↑ Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V., Gaĭnetdinov, R. R. (August 1995). "[The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**58**(4): 8–11.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
7. ↑ Mikhaylova, M; Vakhitova, J; Yamidanov, R; Salimgareeva, M; Seredenin, S; Behnisch, T (2007). "The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats". Neuropharmacology. 53 (5): 601–608. https://doi.org/10.1016%2Fj.neuropharm.2007.07.001
8. ↑ Morozov, I. S., Pukhova, G. S., Avdulov, N. A., Sergeeva, S. A., Spasov, A. A., Iezhitsa, I. N. (February 1999). "[The mechanisms of the neurotropic action of bromantan]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**62**(1): 11–14.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
9. ↑ Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., Morozov, I. S. (April 2002). "Toxic effect of single treatment with bromantane on neurological status of experimental animals".*Bulletin of Experimental Biology and Medicine*.**133**(4): 380–383.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1023/a:1016206306875](//doi.org/10.1023%2Fa%3A1016206306875).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0007-4888](//www.worldcat.org/issn/0007-4888).
10. ↑ Morozov, I. S., Klimova, N. V., Karpova, T. D., Shestopalov, S. S. (April 1999). "[The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]".*Eksperimental’naia I Klinicheskaia Farmakologiia*.**62**(2): 3–6.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0869-2092](//www.worldcat.org/issn/0869-2092).
11. ↑ Iëzhitsa IN, Bugaeva LI, Spasov AA, Morozov IS (2000).["[Effect of bromantane on the rat neurologic status in two month course]"](https://pubmed.ncbi.nlm.nih.gov/11109517/).*Eksp Klin Farmakol*(in Russian).**63**(5): 13–7.[PMID](http://en.wikipedia.org/wiki/PubMed_Identifier)[11109517](//www.ncbi.nlm.nih.gov/pubmed/11109517).
12. ↑ Vakhitova, I. V., Iamidanov, R. S., Vakhitov, V. A., Seredenin, S. B. (April 2005). "[DNA macroarray analysis of gene expression changes in rat brain after single administration of 2-aminoadamantane compound]".*Molekuliarnaia Biologiia*.**39**(2): 276–285.[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0026-8984](//www.worldcat.org/issn/0026-8984).
13. ↑ [https://pubmed.ncbi.nlm.nih.gov/21322821/](https://pubmed.ncbi.nlm.nih.gov/21322821/)
14. ↑ ["Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG)"](https://www.gesetze-im-internet.de/btmg_1981/BJNR106810981.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
15. ↑ ["Neue-psychoaktive-Stoffe-Gesetz (NpSG)"](https://www.gesetze-im-internet.de/npsg/BJNR261510016.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
16. ↑ ["§ 2 AMG"](https://www.gesetze-im-internet.de/amg_1976/__2.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 28, 2019.
17. ↑ Prof. Dr. Helmut Pollähne (July 11, 2014).["Cannabinoide Kräutermischungen vor dem EuGH: Legal Highs bleiben legal"](https://www.lto.de/recht/hintergruende/h/eugh-urteil-c35813-c18114-legal-highs-kein-arzneimittel-strafbar-amg-btmg/)[Cannabinoid herbal mixtures at the ECJ: Legal highs stay legal] (in German). LTO. Retrieved December 28, 2019.
18. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.NewPP limit report Cached time: 20251218075221 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.028 seconds CPU time usage: 0.306 seconds Real time usage: 0.660 seconds Preprocessor visited node count: 1564/1000000 Post‐expand include size: 100399/2097152 bytes Template argument size: 11508/2097152 bytes Highest expansion depth: 22/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 22541/5000000 bytes Lua time usage: 0.290/7 seconds Lua virtual size: 8.52 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 558.233 1 -total 51.71% 288.670 11 Template:Cite_journal 19.53% 109.018 1 Template:Effects/base 19.13% 106.799 1 Template:Effect_list 18.69% 104.353 2 Template:Effect_column 17.68% 98.715 1 Template:Effects/physical 17.31% 96.643 2 Template:Effect_panel 16.81% 93.862 8 Template:Citation_needed 10.88% 60.721 1 Template:SubstanceBox/Bromantane 10.33% 57.690 1 Template:SubstanceBox